¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"multiple inhibition analysis"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 4 ÆäÀÌÁö: 1
¿µ¹® semen analysis ÇÑ±Û Á¤¾× °Ë»ç
¼³¸í   
  ºÎºÎ¿¡°Ô¼­ ÀÓ½ÅÀÌ ¾ÈµÇ´Â °æ¿ì ½Ç½ÃÇϴ ºÒÀÓ °Ë»çÁßÀÇ Çϳª·Î Á¤¾×ÀÇ ¾ç, Á¤ÀÚÀÇ ¿îµ¿¼º, ¸ð¾ç, ¼ö µîÀ» ÃøÁ¤ÇÑ´Ù.
¿µ¹® multiple sclerosis ÇÑ±Û ´Ù¹ß°æÈ­Áõ
¼³¸í   
  ½Å°æÃà»èÀ» µÑ·¯½Î°í Àִ ¸»ÀÌÁý(myelin sheath)ÀÇ ÆÄ±«·Î ÀÎÇÑ º´Àû»óŸ¦ ¸»ÇÔ. ÆÄ±«µÈ ¸»ÀÌÁýÀº ÈäÅ͸¦ ³²±â°Ô µÇ¾î ½Å°æÃà»èÀ» ÅëÇÑ ½Å°æÀü´ÞÀÌ Á¦´ë·Î µÇÁö ¾Ê¾Æ ¿îµ¿, °¨°¢, ÀÚÀ²½Å°æ ¸ðµÎÀÇ ½Å°æÀü´ÞÀå¾Ö°¡ ³ªÅ¸³­´Ù. ÀÌ º´Åʹ ¾îµð¼­³ª ³ªÅ¸³¯ ¼ö À־ ±× Àå¾Ö°¡ ³ªÅ¸³ª´Â ºÎÀ§¿¡ µû¶ó ¼­·Î ´Ù¸¥ Áõ»óÀ» È£¼ÒÇÑ´Ù.
¿µ¹® multiple myeloma ÇÑ±Û ´Ù¹ß°ñ¼öÁ¾
¼³¸í   
  ´Ù¹ß¼º ¿ø¹ß¼º°ñÁ¾¾ç. ¸Ó¸®»À-°¥ºñ»À-º¹Àå»À-ôÃß»À-°ñ¹Ý µî¿¡ Àß ³ªÅ¸³ª°í, ¹°··¹°··ÇÑ Á¾±«¸¦ Çü¼ºÇϸç, »ÀÀÇ Èí¼ö°¡ ÀϾ°í, 40~60¼¼ ³²ÀÚ¿¡°Ô ¸¹ÀÌ ¹ß»ýÇÑ´Ù. °ñ¼öÁ¾ Á¾¾ç¼¼Æ÷´Â ÇüÁú¼¼Æ÷¿¡¼­ À¯·¡ÇÑ °ÍÀ̾ ÇüÁú¼¼Æ÷Á¾À̶ó°íµµ ÇÑ´Ù. °ú°Å¿¡´Â ÇüÁú¼¼Æ÷¼º°ñ¼öÁ¾ À̿ܿ¡´Â ´Ù¸¥ °ñ¼öÁ¶Ç÷¿ä¼Ò¿¡¼­ »ý±â´Â °ñ¼öÁ¾À̶ó°í »ý°¢ÇßÁö¸¸ ÇöÀç´Â ºÎÁ¤µÇ°í ÀÖ´Ù. ÇüÁú¼¼Æ÷´Â ¿ø·¡ ¸é¿ª±Û·ÎºÒ¸°À» »ý»êÇϴ ¼¼Æ÷À̸ç, ±×°ÍÀÌ Á¾¾çÈ­ÇÑ ´Ù¹ß °ñ¼öÁ¾ È¯ÀÚ¿¡¼­µµ ´ëºÎºÐ Ç÷û ¼Ó¿¡ ¸é¿ª ±Û·ÎºÒ¸°ÀÌ Áõ°¡µÈ °ÍÀ» º¼ ¼ö ÀÖ´Ù. Áõ°¡ÇÑ ±Û·ÎºÒ¸°Àº IgG³ª IgAÀΠ°æ¿ì°¡ ¸¹Áö¸¸ ´Ù¸¥ Çüµµ ÀÖ´Ù. °ñ¼öÁ¾ È¯ÀÚ ¾à 50%´Â ¿ÀÁÜ¿¡¼­ º¥½ºÁÔ½º´Ü¹éÁúÀÌ °ËÃâµÇ´Âµ¥, ÀÌ ´Ü¹éÁúÀÇ ÃàÀû¿¡ ÀÇÇØ ¿ä¼¼°üÀÌ ÆÄ±«µÇ°í, ÄáÆÏ°æÈ­°¡ ÀϾ´Ù. °ñ¼öÁ¾ È¯ÀÚ¿¡¼­´Â Ç÷û´Ü¹é ÀÌ»óÀ¸·Î °¡²û ¾Æ¹Ð·ÎÀ̵åÁõÀÌ ³ªÅ¸³­´Ù. »À X¼± ¼Ò°ßÀ¸·Î¼­´Â µµ·Á³½ º´ÅÍ, °ñÀ¶ÇØ»ó, º´Àû°ñÀýÀÌ °üÂûµÈ´Ù.
¿µ¹® multiple personality ÇÑ±Û ´ÙÀμº ÀΰÝ
¼³¸í   
  Çظ®¼º Á¤½ÅÀå¾ÖÀÇ Çϳª·Î ³ªÅ¸³­´Ù. ÇÑ »ç¶÷ÀÌ ¿©·¯ »ç¶÷ÀÇ ¼º°ÝÀ» ¼ÒÀ¯Çϰí Àִ °ÍÀ¸·Î ¸¶Ä¡ ¡°Áöų¹Ú»ç¿Í ÇÏÀ̵堾¾¡±¿Í °°Àº °æ¿ìÀÌ´Ù. ¾Æ¸¶, ÇöÀç ÀÚ½ÅÀǠóÁö¿¡¼­ ¹þ¾î³ª°í ½ÍÀº ¹«ÀǽÄÀûÀΠ¿å¸Á¿¡¼­ ºñ·ÔµÇ´Â °ÍÀ¸·Î ¿©°ÜÁø´Ù.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • antidromic inhibition
    ¿ª¹æÇâ¾ïÁ¦
  • afferent inhibition
    µé½Å°æ¾ïÁ¦, ±¸½É¾ïÁ¦
  • agar gel precipitin inhibition test
    ¿ì¹«°Öħ°­¼Ò¾ïÁ¦°Ë»ç
  • allogenic inhibition
    µ¿Á¾ÀÌÇü¾ïÁ¦
  • competitive inhibition
    °æÀï¾ïÁ¦
  • complement fixation inhibition test
    º¸Ã¼°áÇÕ¾ïÁ¦°Ë»ç
  • contact inhibition
    Á¢Ã˾ïÁ¦
  • density dependent inhibition
    ¹ÐµµÀÇÁ¸¾ïÁ¦
  • enzyme inhibition
    È¿¼Ò¾ïÁ¦
  • feedback inhibition
    µÇ¸ÔÀÓ¾ïÁ¦
  • hemagglutination inhibition antibody
    ÀûÇ÷±¸ÀÀÁý¾ïÁ¦Ç×ü
  • hemagglutination inhibition test
    Ç÷±¸ÀÀÁý¾ïÁ¦°Ë»ç
  • hemagglutination-inhibition reaction
    ÀûÇ÷±¸ÀÀÁý¾ïÁ¦¹ÝÀÀ
  • irreversible inhibition
    ºñ°¡¿ª¾ïÁ¦
  • immunologic inhibition
    ¸é¿ª¾ïÁ¦
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • inhibition
    ¾ïÁ¦, ÀúÁö
  • competitive inhibition
    °æÀï¾ïÁ¦
  • reciprocal inhibition
    »ó¹Ý¾ïÁ¦, »óÈ£¾ïÁ¦
  • inhibition reaction
    ¾ïÁ¦¹ÝÀÀ
  • inhibition test
    ¾ïÁ¦°Ë»ç
  • multiple birth
    ´Ù»ê, ´ÙÅÂÃâ»ê
  • plural multiple birth
    ´Ù»ê, ´ÙÅÂÃâ»ê
  • multiple
    ´Ù¹ß-, ¿©·¯-, ¹µ-, ´Ù-
  • multiple myeloma
    ´Ù¹ß°ñ¼öÁ¾
  • multiple endocrine neoplasia
    º¹ÇÕ³»ºÐºñ»ù½Å»ý¹°
  • multiple sclerosis
    ´Ù¹ß°æÈ­Áõ
  • multiple causation theory
    Áúº´¹ß»ý´Ù¿äÀμ³
  • analysis
    ºÐ¼®
  • antigen analysis
    Ç׿øºÐ¼®
  • path analysis
    °æ·ÎºÐ¼®
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • afferent inhibition
    µé½Å°æ¾ïÁ¦, ±¸½É¾ïÁ¦
  • agar gel precipitin inhibition test
    ¿ì¹«°Öħ°­¼Ò¾ïÁ¦°Ë»ç
  • allogenic inhibition
    µ¿Á¾ÀÌÇü¾ïÁ¦
  • antidromic inhibition
    (¢¡recurrent inhibition) ȸ±Í¾ïÁ¦
  • hemagglutination inhibition antibody
    ÀûÇ÷±¸ÀÀÁý¾ïÁ¦Ç×ü
  • colony inhibition test
    ¼¼Æ÷±ºÇü¼º¾ïÁ¦°Ë»ç, Áý¶ôÇü¼º¾ïÁ¦°Ë»ç
  • competitive inhibition
    °æÀï¾ïÁ¦, °æÇÕ¾ïÁ¦
  • complement fixation inhibition test
    º¸Ã¼°áÇÕ¾ïÁ¦½ÃÇè
  • contact inhibition
    Á¢Ã˾ïÁ¦
  • density dependent inhibition
    ¹ÐµµÀÇÁ¸¾ïÁ¦
  • enzyme inhibition
    È¿¼Ò¾ïÁ¦
  • feedback inhibition
    µÇ¸ÔÀÓ¾ïÁ¦
  • fertility inhibition
    ¼öÅÂÀÎÀÚÀü´ÞÀúÁö
  • migration inhibition factor
    Æ÷½Ä¼¼Æ÷À̵¿ÀúÇØÀÎÀÚ
  • hemagglutination inhibition test
    Ç÷±¸ÀÀÁý¾ïÁ¦°Ë»ç
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • Cowdens syndrome = multiple hamartoma syndrome
    ´Ù¹ß¼º °ú¿ÀÁ¾ ÁõÈıº
  • MOTSA (multiple overlapping thin-slab acquisition)
    ´ÙÁß Áߺ¹ ¼¼ÆíÆÇ ȹµæ
  • infection, multiple
    ´ÙÁß°¨¿°, º¹¼ö±Õ°¨¿°
  • infectious multiple gangrene of skin
    Àü¿°¼º ÇǺΠ´Ù¹ß¼º ±«Àú
  • personality disorder, multiple
    ´ÙÁß(Òýñì) ÀΰÝÀå¾Ö
  • personality, multiple
    ´ÙÁßÀΰÝ.
  • plural birth =multiple b.
    ´Ùźи¸(Òý÷à ÝÂØ´).
  • DNA sequence analysis
    DNA ¼­¿­ºÐ¼®
  • Data analysis
    Á¤º¸ºÐ¼®
  • Decision analysis
    °áÁ¤ºÐ¼®
  • activation analysis
    Ȱ¼ºÈ­ºÐ¼®(¡­ÝÂà°), ¹æ»çÈ­(Û¯ÞÒûù)ºÐ¼®.
  • activation analysis
    ¹æ»çÈ­ºÐ¼®, Ȱ¼ºÈ­ºÐ¼®
  • amniotic fluid analysis
    ¾ç¼öºÐ¼®
  • analysis
    ºÐ¼®
  • analysis of variance technique
    ºÐ»ê±â¼úºÐ¼®
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • afferent inhibition
    ±¸½É¼º ¾ïÁ¦(Ï´ãýàõåäð¤)
  • agar gel precipitin inhibition test
    ÇÑõ°Öħ°­¼Ò ÀúÁö½ÃÇè(¡­ ˽áÈðæò­ãËúÐ).
  • agglutination inhibition test
    ÀÀÁý¾ïÁ¦½ÃÇè(¡­åäð¤ãËúÐ).
  • allogen(a)ic inhibition
    µ¿Á¾¼¼Æ÷ÀúÁö(¡­á¬øàðæò­).
  • antidromic inhibition
    ¿ª¹æÇ⼺ ¾ïÁ¦ (¡­åäð¤)
  • cardiac inhibition
    ½ÉÀå ¾ïÁ¦(ãýíôåäð¤)
  • cell,contact inhibition
    Á¢Ã˾ïÁ¦ (ïÈõºåäð¤)
  • chemical inhibition isoagglutinin
    È­ÇÐÀû ¾ïÁ¦ µ¿Á¾ÀÀÁý¼Ò
  • colony inhibition
    ±ÕÁý¶ô¾ïÁ¦(жó¢Õªåäð¤), ±ºÃ¼¾ïÁ¦(ÏØô÷åäð¤).
  • colony inhibition test
    Áý¶ôÇü¼º ÀúÁö½ÃÇè, ¼¼Æ÷±ºÇü¼º ÀúÁö½ÃÇè
  • competitive antagonism/inhibition
    °æÀïÀû ±æÇ×/¾ïÁ¦.
  • competitive inhibition
    °æÀïÀû ¾ïÁ¦, °æÇÕ¼º ¾ïÁ¦(Ìæùêàõåäð¤).
  • competitive inhibition
    °æÇÕÀúÇØ(ÌæùêîÁúª).
  • competitive inhibition
    °æÀïÀû¾ïÁ¦
  • competitive inhibition
    °æÀïÀû¾ïÁ¦
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 3 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • Multiple placenta
    ¹µÅ¹Ý
    [¿¾ ¿ë¾î] ´Ù¹ß¼ºÅ¹Ý
  • Multiple deformity
    º¹ÇÕ±âÇü
    [¿¾ ¿ë¾î] ´Ù¹ß¼º±âÇü
  • Multiple morphologic defect
    º¹ÇÕÇüŰáÇÔ
    [¿¾ ¿ë¾î] ´Ù¹ß¼ºÇüÅÂÇÐÀû°áÇÔ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 2 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • multiple budding
    ´Ù¼öÃâ¾Æ
  • multiple fission
    ´ÙºÐ¿­
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 1 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • multiple inhibition analysis
    ´ÙÁß(Òýñì)ÀúÇØ ºÐ¼®(îÁúªÝÂà°)
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • inhibition analysis
    ÀúÇØºÐ¼®(îÁúªÝÂà°)
  • multiple alleles
    º¹´ë¸³À¯ÀüÀÚ(ÜÜÓߨ¡ë¶îîí­)
  • multiple binding
    ´ÙÁß°áÇÕ(ÒýñëÌ¿ùê)
  • multiple codon recognition
    ´Ù(Òý)ÄÚµ· ÀÎÁö(ìãò±)
  • multiple displacement mechanism
    ´Ù(Òý)´ëü(ÓÛôð) ±âÀü(Ѧï®)
  • multiple factor hypothesis
    ´ÙÀÎÀÚ¼³(Òýì×í­àã)
  • multiple gene
    ´ÙÀ¯ÀüÀÚ(Òýë¶îîí­)
  • activation analysis
    Ȱ¼ºÈ­ºÐ¼® (üÀàõûùÝÂà°)
  • amino acid analysis
    ¾Æ¹Ì³ë»ê(ß«) ºÐ¼®(ÝÂà°)
  • analysis of variance
    ºÐ»êºÐ¼®(ÝÂߤÝÂà°)
  • conformational analysis
    ÀÔüÇüÅ ºÐ¼®(Ø¡ô÷û¡÷¾ÝÂà°)
  • control analysis
    ´ëÁ¶ ºÐ¼®(ÓßðÎÝÂà°)
  • covalent structure analysis
    °øÀ¯°áÇÕ ±¸Á¶ºÐ¼®(ÍìêóÌ¿ùêϰðãÝÂà°)
  • differential thermal analysis
    Â÷ ¿­ºÐ¼®(ó¬æðÝÂà°)
  • displacement analysis
    ´ëÄ¡ºÐ¼®(ÓÛöÇÝÂà°)
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • hemagglutination inhibition test
    Ç÷±¸ÀÀÁý¾ïÁ¦½ÃÇè
  • inhibition
    ¾ïÁ¦, ÀúÁö, ÀúÇØ
  • MOTSA [=multiple overlapping thin-slab acquisition]
    ´ÙÁßÁߺ¹¼¼ÆíÆÇȹµæ
  • multiple
    ´Ù¹ß¼º
  • multiple cranial nerve palsy
    ´Ù¹ß¼º³ú½Å°æ¸¶ºñ
  • multiple echo
    ´ÙÁß¿¡ÄÚ
  • multiple epiphyseal dysplasia
    ´Ù¹ß¼º°ñ´ÜÀÌÇü¼ºÁõ
  • multiple excitaiton
    ´ÙÁß¿©±â
  • multiple exostoses
    ´Ù¹ß¼º¿Ü°ñÁõ
  • multiple fibroma
    ´Ù¹ß¼º¼¶À¯Á¾
  • multiple lymphomatous polyposis
    ´Ù¹ß¼º¸²ÇÁÁ¾¼º¿ëÁ¾Áõ
  • multiple myeloma
    ´Ù¹ß¼º°ñ¼öÁ¾
  • multiple overlapping thin slab acquisition [=MOTSA]
    ´ÙÁßÁߺ¹¼¼ÆíÆÇȹµæ
  • multiple polyp
    ´Ù¹ß¼ºÆú¸³
  • multiple sclerosis
    ´Ù¹ß¼º°æÈ­Áõ
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 1
ECG Electro-Cardio-Graphy(-Gram); ½ÉÀüµµ
   = EKG
  1. Conducting System Structu...
RI radiation intensity; radioactive isotope; radioimmunology; recession index; recombinant inbred [stra...
SA salicylic acid; saline [solution]; salt added; sarcoidosis; sarcoma; scalenus anticus; secondary ame...
EIC elastase inhibition capacity; enzyme inhibition complex
LAI latex particle agglutination inhibition; leukocyte adherence inhibition
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 1
MANOVA Multiple Analysis of Variance
MCA Multiple Classification Analysis
ACEi Angiotensin I converting enzyme inhibition
BIS Behavioral Inhibition System
CEI Converting enzyme inhibition
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • single-factor versus multiple-factor analysis
    ´ÜÀÏ ¿ä¼Ò ºÐ¼® ´ë º¹ÇÕ ¿ä¼Ò ºÐ¼®
  • multiple fission,multiple division
    ´Ù ºÐ¿­
    1°³ÀÇ ¸ð¼¼Æ÷°¡ ÀϽÃÀûÀ¸·Î ´Ù¼öÀÇ µþ ¼¼Æ÷·Î ³ª´©¾îÁö´Â ÀÏ. º¹ ºÐ¿­À̶ó°íµµ ÇÑ´Ù. ¸ðü°¡ 2°³ÀÇ µþ °³Ã¼·Î ³ª´©¾îÁö´Â 2ºÐ¿­¿¡ ´ëÇÏ¿© ÀϽÿ¡ ´Ù¼öÀÇ µþ °³Ã¼·Î ºÐ¿­ÇÏ´Â Çö»óÀ» ¸»ÇÑ´Ù. ¿ø»ýµ¿¹° Æ÷ÀÚÃæ·ùÀÇ Áõ¿ø»ý½Ä µî¿¡¼­ º¼ ¼ö ÀÖ´Ù. Áï, ÇÙ¸¸ÀÌ ºÐ¿­À» µÇÇ®ÀÌÇÏ¿© ´ÙÇÙü°¡ µÈ µÚ¿¡ ¼¼Æ÷ÁúÀÌ ÀÏÁ¦È÷ ºÐ¿­ÇÏ¿© °¢°¢ ÇÙ 1°³¾¿À» ÇÔÀ¯ÇÏ´Â µþ °³Ã¼·Î ³ª´©¾îÁø´Ù.
  • allogeneic inhibition
    µ¿Á¾ ÀÌÇü ¾ïÁ¦
  • antagonistic inhibition
    ±æÇ×±Ù ¾ïÁ¦, ±æÇ×Àû ¾ïÁ¦, ±æÇ×Àû ÀúÇØ
  • antidromic inhibition
    ¿ª¹æÇ⼺ ¾ïÁ¦
  • competitive inhibition
    °æÀïÀû ¾ïÁ¦, °æÇÕ¼º ¾ïÁ¦
    ¾î¶² ¼ö¿ëü¿¡ ´ëÇØ °áÇÕ·ÂÀÌ Å« ¹°ÁúÀÌ »ó´ëÀûÀ¸·Î °áÇÕ·ÂÀÌ ¾àÇÑ ´Ù¸¥ ¹°ÁúÀÇ °áÇÕÀ» ¾ïÁ¦ÇÏ´Â °Í.
  • complement fixation inhibition test
    º¸Ã¼ °íÁ¤ ÀúÇØ ½ÃÇè
  • cyto- ¼¼Æ÷¿ÍÀÇ °ü°è¸¦ ³ªÅ¸³»´Â Á¢µÎ¾î.

    cyto-inhibition

    ¼¼Æ÷ ¾ïÁ¦ ÀÛ¿ë
    ޽ÄÇÑ ¼¼±Õ ¶Ç´Â ¹ÙÀÌ·¯½º¸¦ ¿ëÇØÇϰųª È­Çпä¹ýÁ¦¿¡ ÀÇÇÑ È­ÇÐÀû ÆÄ±«·ÎºÎÅÍ ¹æ¾îÇÏ´Â ½Ä ¼¼Æ÷ÀÇ ÀÛ¿ë.
  • enzyme inhibition
    È¿¼Ò ¾ïÁ¦
  • factor macrophage migration inhibition
    ´ë½Ä ¼¼Æ÷ À¯ÁÖ ÀúÁö ÀÎÀÚ
  • hapten inhibition test
    ÇÕÅÙ ÀúÇØ ½ÃÇè
    Ç×üÀÇ Ç׿ø Ư¼ö °áÇÕ ºÎÀ§¸¦ µ¤´Â ÇÕÅÙÀ» ÀÌ¿ëÇÏ¿© Ç׿ø °áÁ¤±âÀÇ Ç÷ûÇÐÀû Ư¼ºÀ» °Ë»çÇÏ´Â ½ÃÇè.
  • hemagglutination inhibition test
    ÀûÇ÷±¸ ÀÀÁý ¾ïÁ¦ ½ÃÇè
  • inhibition
    ¾ïÁ¦, ÀúÁö, ÀúÇØ
    °úÁ¤ÀÇ ¾ï¾Ð
  • inhibition reaction
    ¾ïÁ¦, ¾ïÁ¦ ¹ÝÀÀ, ÀúÁö, ÀúÁö ¹ÝÀÀ
  • inhibition zone
    ¾ïÁ¦´ë
    ħ°­ ¶Ç´Â ÀÀÁý ¹ÝÀÀ¿¡¼­ Ç×ü ³óµµ°¡ ³ôÀº Ç÷û¿¡¼­´Â Ç׿ø ÀÔÀÚ¿Í ¹ÝÀÀÀ» ³ªÅ¸³»Áö ¾Ê´Â Çö»ó.
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
allogeneic inhibition Inhibition or injury to allogeneic cells that occurs when lymphocytes are mixed and cultured with other cells of different genotypes in vitro.
(05 Mar 2000)
macrophage inhibition factor <cytokine> A group of lymphokines (including a 14 kD glycoprotein) produced by activated T lymphocytes that reduces macrophage mobility and probably increases macrophage macrophage adhesion.
(18 Nov 1997)
macrophage migration inhibition test A test which measures the presence of migration-inhibitory factor. Usually peritoneal macrophages are placed in a capillary tube in the presence or absence of supernatants from activated T-cells. If MIF is present, the migration of monocyte/macrophages is reduced.
Synonym: macrophage migration inhibition test, migration inhibition test.
(05 Mar 2000)
reactive inhibition Tendency toward a lessened strength of response due to practice or activity. It is independent of the effect of reward and is a direct function of time interval since the last response and the number of preceding responses.
(12 Dec 1998)
reciprocal inhibition Contraction in a muscle is accompanied by a loss of tone or by relaxation in the antagonistic muscle.
Synonym: reciprocal inhibition.
(05 Mar 2000)
reflex inhibition A situation in which sensory stimuli decrease reflex activity.
(05 Mar 2000)
cell migration inhibition Phenomenon of cell-mediated immunity measured by in vitro inhibition of the migration or phagocytosis of antigen-stimulated leukocytes or macrophages. Specific assays have been developed to estimate levels of migration-inhibitory factor, immune reactivity against tumour-associated antigens, and immunosuppressive effects of infectious microorganisms.
(12 Dec 1998)
central inhibition <physiology> Suppression or diminution of outgoing impulses from a reflex centre.
(05 Mar 2000)
residual inhibition The inhibition or suppression of tinnitus by use of a sound-generating device (residual inhibitor) which masks the sounds of tinnitus and produces a residual sound-inhibiting effect when the device is turned off.
(05 Mar 2000)
retroactive inhibition The partial or complete obliteration of memory by a more recent event, particularly new learning.
Compare: proactive inhibition.
(05 Mar 2000)
migration inhibition test A test which measures the presence of migration-inhibitory factor. Usually peritoneal macrophages are placed in a capillary tube in the presence or absence of supernatants from activated T-cells. If MIF is present, the migration of monocyte/macrophages is reduced.
Synonym: macrophage migration inhibition test, migration inhibition test.
(05 Mar 2000)
Wedensky inhibition Inhibition of muscle response resulting from application of a series of rapidly repeated stimuli to the motor nerve where slower frequency of stimulation results in muscle response.
(05 Mar 2000)
competitive inhibition <chemistry> Inhibitor that occupies the active site of an enzyme or the binding site of a receptor and prevents the normal substrate or ligand from binding.
at sufficiently high concentration of the normal ligand inhibition is lost: the Km is altered by the competitive inhibitor, but the Vmax remains the same.
(05 Jan 1998)
contact inhibition The inhibition of continued growth and division of a cell or colony due to physical contact with other cells or colonies. The stopping of continued growth when a certain density of cells has been reached.
The momentary stopping of all movement when a mobile cell runs into another cell.
(09 Oct 1997)
contact inhibition of growth See: density dependent inhibition.
(18 Nov 1997)
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • inhibition
    ¾ïÁ¦
  • feedback inhibition
    Çǵå¹é ÀúÇØ
  • inhibition
    ±ÝÁö;±ÝÁ¦;¾ïÁ¦;¾ï¾Ð;(¿µ±¹±³)¼º¹«ÁýÇà±ÝÁö¸í·É;(¿µ¹ý)¼Ò¼ÛÁøÇàÁ¤Áö¿µÀå
  • common multiple
    °ø¹è¼ö
  • multiple
    º¹ÇÕÀÇ;´Ù¾çÇÑ;¹è¼öÀÇ;¹è¼ö;¹è¼ö·®(least common multiple ÃÖ¼Ò °ø¹è¼ö)
  • multiple choice test
    ¼±´ÙÇü Å×½ºÆ®
  • multiple cropping
    ´Ù¸ðÀÛ
  • multiple farming
    ´Ù°¢ ³ó¾÷
  • multiple shop
    ¿¬¼âÁ¡
  • analysis
    ºÐÇØ
  • analysis
    ºÐ¼®;ÇØ¼®;ºÐÇØ
  • conformational analysis
    ¹èÁÂ ÇØ¼®
  • content analysis
    ³»¿ë ºÐ¼®
  • critical path analysis (method)
    Å©¸®Æ¼Äà ÆÐ½º ºÐ¼®¹ý(ÇÁ·ÎÁ§Æ®ÀÇ °èȹ.°ü¸®¸¦ °úÇÐÀûÀ¸·Î ÇÏ´Â ¹æ¹ý)
  • dream analysis
    ²Þ ºÐ¼®
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 1
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 1
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 1
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 1
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 1
ÅëÇÕ°Ë»ö ¿Ï·á